An observational study in Ventilator-associated Pneumonia, sponsored by University Hospital, Limoges. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by University Hospital, Limoges · Observational
Diagnosis of VAP relies on a set of non-specific clinical, biological, and imaging criteria.
Understanding host-pathogen interactions and the mechanisms of deregulations leading to infection of pulmonary tissue appears essential.
The aim is to qualitatively describe the B lymphocyte populations present in the pulmonary microenvironment of patients admitted to intensive care and requiring invasive mechanical ventilation
The study of the immune system and host-pathogen interactions is the subject of extensive research to improve the understanding of pathophysiology, leading to more precise diagnostic criteria, and considering preventive or curative treatments while limiting the use of anti-infective molecules. Understanding host-pathogen interactions and the mechanisms of deregulations leading to infection of pulmonary tissue seems essential. The study of T lymphocyte populations has already been the focus of numerous investigations. However, regarding the humoral immune response, B lymphocyte populations and their roles have so far been little explored in this context. Nevertheless, the presence of B lymphocytes in pulmonary tissue has been proven, particularly in infectious, postinfectious, or postvaccination contexts, but currently, there are no published studies regarding the B lymphocytes role in the pathophysiology of VAP (Ventilator-Associated Pneumonia).
Respiratory samples (endotracheal aspirates) will be collected from patients under mechanical ventilation on the day of intubation (D0), the day before extubation (Dext), and the day of VAP diagnosis (DVAP) for patients who will develop it. The samples will be stored and then analyzed by flow cytometry.
Patients of Limoges University Hospital admitted to emergency room
Exclusion Criteria:
Patient who developped Ventilator Associated Pneumonia (VAP) under mechanical ventilation
Patient who did not develop Ventilator Associated Pneumonia (VAP) under mechanical ventilation
Qualitative description of B lymphocyte populations by flow cytometry analysis with specific antibodies
To qualitatively describe the B lymphocyte populations in the endotracheal aspirates of patients admitted to intensive care and requiring invasive mechanical ventilation. B lymphocyte subpopulations will be described using a flow cytometry method using antibodies targeting the following markers: CD93, CD62L, CD14, CXCR4, CD32, CD27, CD38, CD138, CD3, CD10, CD19, CD20, kappa light chains, lambda light chains.
Time frame: At the inclusion (T1), at diagnosis (T2 on the day of VAP diagnosis for patient who will develop it, on average 72 hours after the inclusion), at the end of the study (T3 on the day before extubation, on average 5 days after the inclusion)
Quantitative description of B lymphocyte populations by flow cytometry analysis with specific antibodies
To quantitatively describe the B lymphocyte populations in the endotracheal aspirates of patients admitted to intensive care, requiring invasive mechanical ventilation, and presenting ventilator associated pneumonia (VAP). B lymphocyte subpopulations will be described using a flow cytometry method using antibodies targeting the following markers: CD93, CD62L, CD14, CXCR4, CD32, CD27, CD38, CD138, CD3, CD10, CD19, CD20, kappa light chains, lambda light chains
Time frame: At the inclusion (T1), at diagnosis (T2 on the day of VAP diagnosis for patient who will develop it, on average 72 hours after the inclusion), at the end of the study (T3 on the day before extubation, on average 5 days after the inclusion)
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated→
University Hospital, Limoges